Acoramidis slows disease progression in transthyretin amyloid cardiomyopathy

1. In this randomized controlled trial, patients with transthyretin (TTR) amyloid cardiomyopathy exposed to acoramidis had slower disease progression than those on a placebo.  2. There were significantly fewer adverse events in the acoramidis group, along with a higher quality of life.  Evidence Rating Level: 1 (Excellent) Study Rundown: TTR is a transport protein with […]

The post Acoramidis slows disease progression in transthyretin amyloid cardiomyopathy first appeared on 2 Minute Medicine.